Novo Nordisk A/S Prevails In Sanofi-Aventis (New Jersey) Challenge To Levemir(R) -- Up To 24 Hours Duration Of Action And Other Claims Upheld

Novo Nordisk (NYSE: NVO) announced today a victory in a lawsuit in which Sanofi-Aventis sought a preliminary injunction against Novo Nordisk's pre-launch and launch materials for Levemir® (insulin detemir [rDNA origin] injection), Novo Nordisk's new long-acting basal insulin.